Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b extension and crossover study of RSVPreF3 OA revaccination schedules in adults ≥60 years
jRCT2031240222Phase 3Recruiting
- Sponsor
- GSK
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (4 arms), sponsored by GSK. Primary endpoints: RSV-A neutralizing titers (GMTs) in RSV_PreS4 group, RSV-B neutralizing titers (GMTs) in RSV_PreS4 group and 14 more. Started Aug 2024; status: recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031240222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240222.